Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy strategies for urological dysfunction.

M B Chancellor1, N Yoshimura, R Pruchnic

  • 1Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA. chancellormb@msx.upmc.edu

Trends in Molecular Medicine
|June 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.

Osteoarthritis and cartilage·2022
Same author

[Impact of the Lubrizol Rouen plant fire of September 26, 2019 on ophthalmic emergency room visits].

Journal francais d'ophtalmologie·2021
Same author

Bone morphogenetic proteins for articular cartilage regeneration.

Osteoarthritis and cartilage·2018
Same author

αv integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis.

Nature communications·2017
Same author

Evolving paradigms in clinical pharmacology and therapeutics for the treatment of Duchenne muscular dystrophy.

Clinical pharmacology and therapeutics·2016
Same author

NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair.

Cell death & disease·2015
Same journal

Hyocholic acids: Third bile acids for neonatal health.

Trends in molecular medicine·2026
Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
See all related articles

Novel gene therapy and tissue engineering offer new urologic treatments. These techniques show promise for conditions like incontinence, diabetic bladder dysfunction, erectile dysfunction, and benign prostatic hyperplasia.

Area of Science:

  • Urology
  • Regenerative Medicine
  • Molecular Therapy

Background:

  • Minimally invasive and ex vivo approaches are emerging in urology.
  • The lower urinary tract is suitable for advanced therapeutic strategies.
  • Systemic side effects can be minimized with localized treatments.

Purpose of the Study:

  • To review novel molecular techniques in urology.
  • To highlight the potential of gene therapy and tissue engineering.
  • To identify specific targets for urologic conditions.

Main Methods:

  • Review of recent advancements in gene therapy (conventional and ex vivo).
  • Discussion of tissue engineering applications in urology.
  • Analysis of stem cell applications for urinary dysfunction.

Related Experiment Videos

Main Results:

  • Muscle-derived stem cells show success in treating stress incontinence.
  • Nerve growth factor (NGF)-based gene therapy improved diabetic bladder dysfunction in rats.
  • Nitric oxide synthase and caspase-7 are potential gene therapy targets for erectile dysfunction and benign prostatic hyperplasia, respectively.

Conclusions:

  • Gene therapy and tissue engineering represent promising frontiers in urology.
  • Targeted molecular approaches offer potential solutions for various urologic diseases.
  • Ex vivo strategies may reduce systemic risks associated with novel therapies.